Fundraising Fox
Insybio
Austin, US · Founded 2017 · Delaware corporation
Find your way into Insybio
Sign up to see every warm intro you have to Insybio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Insybio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
InSyBio develops the InSyBio Suite, a software platform that applies machine learning and computational intelligence to biological and biomedical data analysis, including bioinformatics and drug development applications. The company builds tools for analyzing protein, biomarker, and other biological datasets, and collaborates on EU research projects.
Founders & leadership
Insybio was founded in 2017 by Christos, Konstantinos, and Aigli.
C
ChristosCo-founder & COOChristos Alexakos holds a Ph.D. in Computer Engineering and Informatics from the University of Patras and has over 12 years of software development experience, including work on research projects in computational intelligence, medical imaging, and bioinformatics; he is co-founder and COO of InSyBio.
K
KonstantinosCo-founder, CTO & Technical Sales ManagerTheofilatos Konstantinos holds degrees in computer engineering from the University of Patras (B.Sc. 2006, M.Sc. 2009, Ph.D. 2013 in bioinformatics), and has been co-founding and serving as CTO of InSyBio since 2013 while also holding a lecturer position in bioinformatics at King's College London's BHF Center since 2017.
A
AigliCo-founder & Product Development ManagerAigli Korfiati holds an MSc in Computer Science and Engineering and a PhD in Computational Methods for Transcriptomics Data Analysis from the University of Patras. She is a machine learning engineer with research contributions in bioinformatics and drug development, and co-founded InSyBio in 2013 to develop computational tools for biological data analysis.
LD
Labros DigonisCo-Founder, CEOLabros Digonis brings over 35 years of executive and consulting experience across ICT, shipping, finance, and life sciences sectors, including roles in top management at multibillion-dollar companies and work on multinational projects in technology and telecom. He has led the development of technology start-ups with international operations and managed technology product launches in finance and energy management.
AA
Angelos AngelouNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$550K disclosed across 1 round · 2018
▶$550KraisedAug 2018 · 5 investors · Other TechnologyRule 506(b)
▶$550KraisedAug 2018 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Angelos AngelouExecutive Officer
- Labros DigonisExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $550K
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
VeriSIM LifeVeriSIM uses machine learning and computational simulation to accelerate drug development, replacing traditional trial-and-error experimentation with computational prediction to improve success rates and reduce animal testing. The company serves pharmaceutical partners and research institutions developing new medicines.
ElucidataElucidata is a company oriented around supporting scientific research, emphasizing making users' research more efficient and respecting the scientific method. The available page content does not describe its concrete products or offerings in detail.
PrecisionLifePrecisionLife uses advanced AI and analytics to identify the biological mechanisms underlying complex chronic diseases, enabling earlier diagnosis and more personalized treatment selection. The company develops diagnostic tests, clinical tools, and insights for pharmaceutical and healthcare partners to improve disease understanding and patient outcomes across multiple therapeutic areas.
GenomindGenMedPro is a genetics-based medication management platform that analyzes 26 genes to identify drug-drug and gene-drug interactions across a patient's entire medication regimen. The platform serves healthcare providers and care teams to reduce prescribing errors, prevent adverse events, and optimize medication safety for complex polypharmacy cases.
Sonrai AnalyticsSonrai Analytics provides scientific data analysis services for biomedical research programs, combining bioinformatics, data science, and translational expertise to convert complex datasets into actionable clinical evidence. The company serves research teams and clinical programs globally.
Companies working in the same space as Insybio.
Frequently asked questions
- What does Insybio do?
- InSyBio develops the InSyBio Suite, a software platform that applies machine learning and computational intelligence to biological and biomedical data analysis, including bioinformatics and drug development applications. The company builds tools for analyzing protein, biomarker, and other biological datasets, and collaborates on EU research projects.
- Who founded Insybio?
- Insybio was founded by Christos, Konstantinos, Aigli in 2017.
- How much funding has Insybio raised?
- Insybio has disclosed $550K raised across 1 round.
- Where is Insybio headquartered?
- Insybio is headquartered in Austin, US.